FDA 503A Peptide Compounding Tracker
On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides proposed for the 503A Bulks List— the list of bulk drug substances that compounding pharmacies may legally use. The committee recommended six of the seven, overruling FDA's own reviewers, who had recommended against all of them.
What this vote did not do
- It did not approve any peptide. None of these substances became an FDA-approved drug.
- It did not make anything legal to compound. The vote is advisory. FDA must still complete notice-and-comment rulemaking before the list at 21 CFR 216.23 changes.
- It did not set a deadline. No statute requires FDA to act within any particular period, and no peptide rulemaking date has been announced.
- It did not endorse the uses these peptides are marketed for. FDA reviewed narrow, specific indications — see the table below.
Anyone telling you a peptide is now “FDA approved,” “legalized,” or “unbanned” because of this vote is wrong.
Status of all seven peptides
| Peptide | Indication FDA reviewed | Vote | Outcome | Legal to compound today? |
|---|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8-6, 1 abstention | Recommended | No |
| KPV | Wound healing and inflammatory conditions | 8-6, 1 abstention | Recommended | No |
| TB-500 | Wound healing | 8-6, 1 abstention | Recommended | No |
| MOTS-c | Obesity and osteoporosis | 7-5 | Recommended | No |
| Semax | Cerebral ischemia, migraine and trigeminal neuralgia | 8-5 | Recommended | No |
| Epitalon | Insomnia | 7-5, 1 abstention | Recommended | No |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia and narcolepsy | 6-7, 1 abstention | Rejected | No |
Every vote total above is a reported tally. FDA had not published official minutes or a transcript for this meeting as of 2026-07-28. Rows marked with a have an unresolved abstention count or conflicting reporting; the detail is on each peptide's page.
The gap between what FDA reviewed and what clinics advertise
This is the part of the story that has been largely missed. FDA did not assess these peptides as general wellness or recovery products. It assessed each one against a narrow clinical need — and in several cases that need has almost nothing to do with why people actually buy them.
What has to happen before any of this changes
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Existing 503A list proceedings have taken years to run from proposed rule to final rule. Until a final rule takes effect, a favorable recommendation is not list status. FDA can also decline to follow the committee entirely.
What happens next
FDA has signalled another PCAC meeting before the end of february 2027 to consider five more peptides:
The exact date remains TBD — no dated entry appeared on FDA's advisory committee calendar as of 2026-07-28.
Stay Updated
Get notified when new peptide therapy providers join in your area.
Primary sources
Every status on this page traces to FDA's own briefing documents or the Code of Federal Regulations. We link them directly so you can check us.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.